Tectonic Therapeutic reports 2025 financial results and pipeline progress
Tectonic Therapeutic reported 2025 results with $65.2M revenue, R&D rising to $96.3M, and $158.9M cash runway into H2 2027. The company emphasized progress in its targeted protein degrader pipeline, noting late-stage plans for TTX-030 and IND preparations for earlier candidates.
Why it mattersWith $158.9M cash supporting operations into H2 2027 and a late-stage TTX-030 program, investors should re-evaluate near-term financing and.
Entities Mentioned
Tectonic Therapeutic IncLongeveronVivtexNovo NordiskGlobeNewswire
People Mentioned
François Nader